Bionomics (ASX: BNO) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Bionomics Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Bionomics (ASX: BNO)
    Latest News

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Gainers

    These 3 ASX Healthcare shares have soared over 10% today

    The three healthcare shares are well on the rise today. Read on for more details.

    Read more »

    Five stacked building blocks with green arrows, indicating rising inflation or share prices
    Share Market News

    Up almost 1000% in 1 year, the Bionomics (ASX:BNO) share price moves higher

    The Bionomics Ltd (ASX: BNO) share price is in positive territory after announcing a non-renounceable entitlement offer. Here's the details.

    Read more »

    Giant magnet attracting banknotes to symbolise a capital raising.
    Share Market News

    Why the Bionomics (ASX:BNO) share price is climbing today

    The Bionomics Ltd (ASX: BNO) share price is climbing higher today on news it has received commitments for a capital…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Why the Bionomics (ASX:BNO) share price surged 8% higher today

    The Bionomics share price is marching higher after the company announced that it will exclusively licence its BNC101 drug to…

    Read more »

    Speculative

    Bionomics share price jumps 17% on subscription agreement

    The Bionomics Ltd (ASX: BNO) share price is charging higher today on the back of a subscription agreement announcement.

    Read more »

    a woman
    Share Gainers

    Why the Bionomics share price rocketed 43% higher today

    The Bionomics Ltd (ASX:BNO) share price has rocketed higher on Monday after a positive FDA announcement...

    Read more »

    a woman
    Share Market News

    US congressman resigns over ASX insider trading penny stock scandal

    Can you make money in penny stocks?

    Read more »

    a woman
    Share Market News

    Paradigm reports "ground-breaking" osteoarthritis discovery: Is it the real deal?

    Paradigm Biopharmaceuticals (ASX:PAR) is looking to partner with big pharma.

    Read more »

    a woman
    Share Market News

    Why the Bionomics share price is up 40% today

    Bionomics Ltd (ASX: BNO) looks very speculative.

    Read more »

    a woman
    Share Fallers

    Warning: These are the 10 worst small-cap shares of FY 2019

    The fault dear Brutus is not in the stars, it is in ourselves

    Read more »

    a woman
    Share Fallers

    Why the Bionomics share price crashed 37.5% lower today

    The Bionomics Ltd (ASX:BNO) share price has crashed 37.5% lower today following the release of another disappointing study result...

    Read more »

    a woman
    Share Gainers

    Why Altura Mining, Appen, Bionomics, & Newcrest shares climbed higher today

    The Appen Ltd (ASX:APX) share price and the Newcrest Mining Limited (ASX:NCM) share price are two of four climbing notably…

    Read more »

    BNO ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Bionomics

    Bionomics Ltd. is a clinical stage biopharmaceutical company. It engages in the development of novel drug candidates focused on the treatment of serious central nervous system disorders. The company was founded in 1996 and is headquartered in Eastwood, Australia.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Alan David Fisher Non-Executive Director Sep 2016
    Mr Fisher is an experienced corporate advisor and public company director. He has a track record for implementing strategies that enhance shareholder value. His main areas of expertise include mergers and acquisitions, public and private equity raisings, business restructurings and strategic advice. He is Chair of the Risk Management Committee.

    Mr Aaron Weaver Non-Executive Director Jul 2020
    Mr Weaver is a Principal at Apeiron Investments Group Ltd (Apeiron), focused on the life sciences and technology sector. From 2013 - 2017, he was an investment banker at Credit Suisse Group AG in London within the Capital Markets Solutions team, advising on capital structuring and issuances for a full spectrum of corporate issuers from pre-revenue companies to public listed companies. He was a capital markets solicitor at Allen & Overy LLP, London from 2007 - 2013. Mr Weaver currently serves on the board of Bionomics as Apeiron's nominee. He is a director of MagForce AG, LEAF4Life LLC, Alto Neuroscience, Endogena Therapeutics, Inc, Rejuveron Life Sciences AG.
    Dr Errol B De Souza Executive ChairmanExecutive Director Aug 2016
    Dr De Souza is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders. He has experience as an executive in the biopharmaceutical industry, having founded companies (Neurocrine Biosciences Inc.) and served as President and CEO of several public (Biodel Inc.; Synaptic Pharmaceutical Corp.) and private (Archemix Corp. and Neuropore Therapies Inc.) biotech companies. Dr De Souza has raised several hundred million dollars in capital in private and public sectors and has taken companies public (Neurocrine Biosciences IPO) and sold companies (Synaptic sale to Lundbeck) to provide liquidity and build shareholder value. Over Dr De Souza's career, he has served in a number of high-ranking R&D roles, including SVP and US head of R&D for Aventis (1998-2002), co-founder and EVP of R&D at Neurocrine (1992-1998) and Head of CNS at DuPont Merck (1990-1992). Dr De Souza has served on multiple editorial boards, National Institutes of Health (NIH) Committees and is currently a Director of several public and private companies and currently serves as a member of the board of directors of Catalyst Biosciences, Inc. (CBIO), Cyclerion Therapeutics (CYCN) and Royalty Pharma plc (RPRX). He has previously served on the board of directors of several public companies including IDEXX Laboratories (IDXX), Neurocrine Biosciences (NBIX), Palatin Technologies (PTN) and Synaptic Pharmaceuticals (SNAP).
    Mr David Ian Wilson Non-Executive Director Jun 2016
    Mr Wilson is Chairman and founding partner of WG Partners LLP and has over 35 years' experience in investment banking in the City of London. Previously Mr Wilson was CEO of Piper Jaffray Ltd, where he also served as Global Chairman of Healthcare and on the Group Leadership Team. Mr Wilson has held senior positions at ING Barings as Joint Head of UK Investment Banking Group, Deutsche Bank as Head of Small Companies Corporate Finance and UBS as Head of Small Companies Corporate Broking. Mr Wilson was previously Senior Independent Director of Optos plc, a Non-Executive Director of BerGenBio AS. He is member of the Risk Management Committee.
    Dr Jane Ryan Non-Executive Director Sep 2020
    Dr Ryan has over 30 years of international experience in the pharmaceutical and biotechnology industries having worked in Australia, US and UK. She has held senior executive roles in management of research and development programs as well as business development and alliance management. Throughout her career, she has led many fundraising campaigns and licensing initiatives. She is member of the Risk Management Committee.
    Mr Peter Miles Winston Davies Non-Executive Director Jul 2021
    Mr Davies is a 15-year veteran of the financial services industry with multi-sector and multi-function experience. He has a track record in advising private and public company Board of Directors and shareholders of businesses. He has completed numerous M&A transactions across a variety of sectors including healthcare, along with experience in capital raising and restructuring opportunities during his time at Rothschild & Co. Mr Davies is currently an Investment Professional at Apeiron Investments Group Ltd and is Chief Business Officer for Leaf4Life Inc
    Dr Spyridon Papapetropoulos Non-Executive Director Jan 2023
    --
    Ms Suzanne Grace Irwin Company Secretary Apr 2021
    -
    Adrian Hinton Acting Chief Financial Officer
    -
    Suzanne Grace Irwin Company Secretary
    -
    Liz Doolin Vice President Clinical Development
    -
    Connor Bernstein Vice President Strategy and Corporate Development
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Citicorp Nominees Pty Limited <Citibank Ny Adr Dep A/C> 339,875,460 25.11%
    HSBC Custody Nominees (Australia) Limited 318,042,650 23.50%
    BNP Paribas Nominees Pty Ltd Acf Clearstream 73,460,960 5.43%
    BNP Paribas Noms Pty Ltd <DRP> 43,985,676 3.25%
    HSBC Custody Nominees (Australia) Limited <Gsco Customers A/C> 34,633,340 2.56%
    US Register Control A/C\C 32,409,786 2.39%
    Bell Potter Nominees Ltd <Bb Nominees A/C> 28,472,814 2.10%
    Citicorp Nominees Pty Limited 20,002,049 1.48%
    BNP Paribas Nominees Pty Ltd Hub24 Custodial Serv Ltd <Drp A/C> 17,995,687 1.33%
    Merrill Lynch (Australia) Nominees Pty Limited 17,901,124 1.32%
    Mr Jason Howard David Camm 9,102,132 0.67%
    L&M Group Limited 8,884,085 0.66%
    BNP Paribas Noms Pty Ltd <Global Markets Drp> 8,527,043 0.63%
    Forward Vision Vii Lp Series 2 6,830,075 0.50%
    Mr Mark Richard Potter + Mrs Rebecca Amy Potter <Mark & Rebecca Potter A/C> 5,500,000 0.41%
    Charmed5 Pty Ltd 5,000,000 0.37%
    Qualvest Pty Ltd <Lin Super Fund A/C> 5,000,000 0.37%
    Ambria Investors Lp 4,845,050 0.36%
    Provendore Pty Ltd <The Wilks Super Fund A/C> 4,418,550 0.33%
    Welas Pty Ltd <The Wales Family Super A/C> 4,403,719 0.33%

    Profile

    since

    Note